17.07.2019 | Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR CO.DON AG (ISIN: DE000A1K0227), Aktuell
Berlin / Teltow, 17.07.2019, 10:29 a.m. - The negotiations announced on 9 July 2018 with Xintela A.B. regarding the establishment of a joint venture with the aim of developing a stem cell product for the treatment of osteoarthritis are being discontinued.
After careful analysis, the Management Board of CO.DON AG has concluded today that that there is no longer any potential for an agreement to establish a joint venture with Xintela A.B. As a result of the open and constructive discussions, it has now become clear that the assessment of the contribution to be made to the joint venture by the respective parties is too different.Contact:
Matthias Meißner, M.A.
Director Investor Relations / Public Relations
Tel. +49 (0)30-240352330
Fax +49 (0)30-240352309
E-Mail: ir@codon.de
Attachments
- Original document
- Permalink
Disclaimer
co.don AG published this content on 17 July 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 July 2019 08:54:09 UTC